At the news
? BULLISHIMPACT 7/10 8-K filed Aug 6, 2026 at 07:08 ET
Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for ~$450M upfront ($270M cash + $180M stock) plus up to $350M in milestones and low-single-digit royalties on gildeuretinol net sales. Gildeuretinol is a Phase 3 oral therapy for Stargardt disease, a large inherited retinal disease with no FDA-approved therapy. The deal adds a potential blockbuster pipeline asset but carries significant execution risk given top-line data is not expected until H2 2029 and the upfront cash consideration represents a substantial portion of Tarsus's $2.6B market cap.
- Tarsus to acquire Alkeus for ~$450M upfront ($270M cash + $180M stock at $61.38/share)
- Up to $350M in additional milestone payments upon regulatory approval and first commercial sale
- Low-single-digit tiered descending royalties on worldwide gildeuretinol net sales
- Gildeuretinol is a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access